Tecovirimat - SIGA Technologies
Alternative Names: Arestvyr; SIGA-246; ST-246 Form I (monohydrate); ST-246 Form V (hemihydrate); ST-246®; Tecovirimat monohydrate - SIGA Technologies; TPOXXLatest Information Update: 06 May 2024
At a glance
- Originator ViroPharma
- Developer National Institute of Allergy and Infectious Diseases; SIGA Technologies
- Class Antivirals; Benzamides; Cyclopropanes; Fluorinated hydrocarbons; Isoindoles; Organic bridged compounds; Small molecules
- Mechanism of Action Orthopoxvirus p37 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Smallpox
- Registered Monkeypox; Orthopoxvirus infections; Vaccinia
Most Recent Events
- 03 Mar 2024 Pharmacokinetics data from the phase III STOMP/ACTG 5418 trial in Monkeypox presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
- 31 Dec 2023 SIGA technologies completes a clinical trials in Monkeypox (In adults, In children, In adolescents) in UK (PO)
- 12 May 2023 SIGA Technologies completes a phase III trial (In volunteers) (PO, Capsule) in the US (NCT04971109)